Shefferman
Principal executive officer pay for Shefferman, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Protara Therapeutics, Inc. (TARA) FY2022–FY2025
Aligned: paid up as stock roseCAP $1,014,561→$2,309,996 while $100 invested went $11.07→$198.88
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $2.8M | $1.0M |
| FY2023 | $1.9M | $1.3M |
| FY2024 | $1.8M | $4.4M |
| FY2025 | $2.7M | $2.3M |
The company's "$100 invested" index ran $11.07 at FY2022 → $198.88 by FY2025 — an annualized return of 161.9%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 161.9%/yr at TARA ( FY2022–FY2025). See the CEO track-record ranking for context.